Decoding the Genetic Drivers of Disease Activity in Multiple Sclerosis
Multiple sclerosis (MS) is a complex immune-mediated, demyelinating, and neurodegenerative disorder of the central nervous system characterized by striking clinical heterogeneity. Some patients remain clinically stable for years, whereas others experience relapses, radiological activity, and progressive disability despite treatment. The article by Mascia and colleagues addresses this problem by investigating whether inherited genetic variation contributes to medium-term disease activity in relapsing-remitting multiple sclerosis (RRMS), using a four-year follow-up period and the no evidence of disease activity, or NEDA-3, framework as the principal clinical outcome.
Study Design and Patient Cohorts
The investigators analyzed two independent cohorts of RRMS patients recruited at the San Raffaele Hospital MS center in Milan. To reduce treatment-related heterogeneity, the study focused on patients who began therapy with first-line disease-modifying treatments, including interferon-beta, glatiramer acetate, dimethyl fumarate, and teriflunomide. After four years, patients were classified as NEDA if they had no relapses, no neuroradiological activity, and no disability progression; otherwise, they were classified as having evidence of disease activity. This design enabled the authors to study disease activity as a clinically meaningful, medium-term phenotype rather than relying only on short-term relapse outcomes.
Genome-Wide and Gene-Based Genetic Analyses
The study combined genome-wide association analysis with gene-based testing. After quality control and genotype imputation, the authors meta-analyzed more than 6.5 million shared variants across the two cohorts. Although no variant reached conventional genome-wide significance, 23 single nucleotide polymorphisms showed suggestive association with disease activity. The leading signal was located near SERPINE2, a gene linked to coagulation and inflammatory processes, while additional signals implicated genes such as PON2, which is involved in oxidative stress and mitochondrial function. Gene-based analysis identified 1,090 nominally significant genes, including ILRUN, a gene associated with immune regulation and inhibition of pro-inflammatory cytokine production.
From Individual Variants to Biological Networks
A major strength of the article is that it moves beyond single-variant association and applies tissue-specific network analysis. The authors used brain and lymphocyte interactomes from HumanBase to model gene-gene relationships relevant to the central nervous system and immune system, respectively. Through network diffusion and disease-module detection, they identified a brain module containing 228 genes and a lymphocyte module containing 287 genes. These modules shared 167 genes, suggesting that the genetic contribution to MS disease activity is not confined to a single biological compartment but instead reflects coordinated processes spanning neural and immune tissues.
Key Genes Emerging from Network Topology
The network approach allowed the researchers to prioritize genes according to their topological importance, not merely their association p-values. In the brain module, OPA1 emerged as a highly ranked connector hub; this gene is central to mitochondrial dynamics, including fusion-fission balance and respiratory chain stability. In both the brain and lymphocyte modules, MPHOSPH9 appeared as a connector hub, notable because it has previously been implicated in MS susceptibility and relapse-related phenotypes. In the lymphocyte module, CCT4 was identified as a prominent connector hub, pointing to possible roles for protein folding and intracellular trafficking pathways that would likely have been overlooked in a conventional GWAS-only interpretation.
Biological Pathways: Inflammation, Mitochondria, and Complement
The pathway analyses highlighted several biologically plausible mechanisms. The brain module showed nominal enrichment for pathways including circadian rhythm, extracellular matrix-receptor interaction, citrate cycle activity, steroid biosynthesis, and complement and coagulation cascades. The lymphocyte module showed enrichment for circadian rhythm, ubiquitin-mediated proteolysis, mRNA surveillance, PPAR signaling, extracellular matrix-receptor interaction, and the citrate cycle. Particularly important is the recurrence of complement and coagulation pathways, which are already implicated in MS inflammatory pathology and chronic active lesions. Together with the involvement of PON2, OPA1, TUFM, and FLAD1, these findings support a model in which oxidative stress, mitochondrial dysfunction, immune activation, and complement-mediated inflammation jointly influence medium-term disease activity.
Significance and Future Directions
This article provides an integrative view of how genetics may contribute to MS disease activity over a clinically meaningful time frame. Its central conclusion is that genetically influenced disease activity appears to operate through shared mechanisms across brain and lymphocyte tissues, rather than through entirely separate central and peripheral pathways. The findings are suggestive rather than definitive, because no single variant reached genome-wide significance and the sample size remains modest for complex-trait genetics. Nevertheless, the study demonstrates the value of combining GWAS, gene-based association, tissue-specific interactomes, and pathway analysis to reveal biologically coherent signals. Future studies in larger, independently replicated cohorts may help validate these candidate genes and pathways and eventually contribute to more individualized prognostic models for patients with multiple sclerosis.
Disclaimer: This blog post is based on the provided research article and is intended for informational purposes only. It is not intended to provide medical advice. Please consult with a healthcare professional for any health concerns.
References:
Mascia, E., Nale, V., Ferrè, L. et al. Genetic Contribution to Medium-Term Disease Activity in Multiple Sclerosis. Mol Neurobiol 62, 322–334 (2025). https://doi.org/10.1007/s12035-024-04264-8
